以Tat为靶点的人类免疫缺陷病毒1型潜伏库治疗策略的研究进展

doi:10.13481/j.1671-587X.20250330

Abstract

Abstract:

Human immunodeficiency virus type 1 （HIV-1） latent reservoirs pose the primary obstacle to curing acquired immunodeficiency syndrome （AIDS）. Transactivator（Tat）， a regulatory protein encoded by HIV-1， influences the establishment and reactivation of latent reservoirs by promoting viral transcription. Inhibitors targeting Tat protein suppress viral rebound by reducing Tat protein levels and disrupting its transcription-promoting functions. Among the two strategies for treating HIV-1 latent reservoirs， the “block-and-lock” strategy， which is based on Tat protein inhibitors， aims to target HIV-1 proteins or host factors while interfering with histone epigenetic modifications， thereby permanently silencing proviral DNA and maintaining HIV-1 latency even after treatment discontinuation. Tat-related inhibitors such as didehydrocortistatin A （dCA）， triptolide， and apalutamide-derived Q308 regulate HIV-1 latency through distinct mechanisms. This review summarizes the regulatory roles of Tat in HIV-1 latency， Tat protein inhibitor-based therapeutic strategies for targeting latent reservoirs， and the mechanisms of action of related inhibitors， with the goal of providing insights for the development of drugs toward achieving functional HIV-1 cure.

Key words: Acquired immunodeficiency syndrome, Transactivator, HIV-1 latent reservoir, “Block-and-lock”strategy, Functional cure

CLC Number:

R512.91

Haobo HU,Chen HUAN. Research progress in therapeutic strategy of human immunodeficiency virus type 1 latenty by targeting Tat[J].Journal of Jilin University(Medicine Edition), 2025, 51(3): 831-838.

Figures/Tables 1

References 53

[1]	VAN HEUVEL Y， SCHATZ S， ROSENGARTEN J F， et al. Infectious RNA： human immunodeficiency virus （HIV） biology， therapeutic intervention， and the quest for a vaccine［J］. Toxins （Basel）， 2022， 14（2）： 138.
[2]	CHEN J， ZHOU T， ZHANG Y， et al. The reservoir of latent HIV［J］. Front Cell Infect Microbiol， 2022， 12： 945956.
[3]	JIN H P， LI D S， LIN M H， et al. Tat-based therapies as an adjuvant for an HIV-1 functional cure［J］. Viruses， 2020， 12（4）： 415.
[4]	KAMORI D， UENO T. HIV-1 tat and viral latency： what we can learn from naturally occurring sequence variations［J］. Front Microbiol， 2017， 8： 80.
[5]	PAU A K， GEORGE J M. Antiretroviral therapy： current drugs［J］. Infect Dis Clin North Am， 2014， 28（3）： 371-402.
[6]	GARCÍA F， PLANA M， VIDAL C， et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy［J］. AIDS， 1999， 13（11）： F79-F86.
[7]	VANSANT G， BRUGGEMANS A， JANSSENS J， et al. Block-and-lock strategies to cure HIV infection［J］. Viruses， 2020， 12（1）： 84.
[8]	LI C， MOUSSEAU G， VALENTE S T. Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat［J］. Epigenetics Chromatin， 2019， 12（1）： 23.
[9]	SILICIANO R F， GREENE W C. HIV latency［J］. Cold Spring Harb Perspect Med， 2011， 1（1）： a007096.
[10]	GARCÍA M， BUZÓN M J， BENITO J M， et al. Peering into the HIV reservoir［J］. Rev Med Virol， 2018， 28（4）： e1981.
[11]	KO A， KANG G B， HATTLER J B， et al. Macrophages but not astrocytes harbor HIV DNA in the brains of HIV-1-infected aviremic individuals on suppressive antiretroviral therapy［J］. J Neuroimmune Pharmacol， 2019， 14（1）： 110-119.
[12]	CASTRO-GONZALEZ S， COLOMER-LLUCH M， SERRA-MORENO R. Barriers for HIV cure： the latent reservoir［J］. AIDS Res Hum Retroviruses， 2018， 34（9）： 739-759.
[13]	POMERANTZ R J， SESHAMMA T， TRONO D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of rev： potential implications for latency［J］. J Virol， 1992， 66（3）： 1809-1813.
[14]	EMILIANI S， FISCHLE W， OTT M， et al. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line［J］. J Virol， 1998， 72（2）： 1666-1670.
[15]	DEEKS S G. HIV： shock and kill［J］. Nature， 2012， 487（7408）： 439-440.
[16]	BOUCHAT S， GATOT J S， KABEYA K， et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients［J］. AIDS， 2012， 26（12）： 1473-1482.
[17]	QI X H， KOYA Y， SAITOH T， et al. Efficient induction of HIV-1 replication in latently infected cells through contact with CD4+ T cells： involvement of NF-kappaB activation［J］. Virology， 2007， 361（2）： 325-334.
[18]	KHOURY G， MOTA T M， LI S， et al. HIV latency reversing agents act through Tat post translational modifications［J］. Retrovirology， 2018， 15（1）： 36.
[19]	GALLO R C. Shock and kill with caution［J］. Science， 2016， 354（6309）： 177-178.
[20]	SCARBOROUGH R J， GATIGNOL A. RNA interference therapies for an HIV-1 functional cure［J］. Viruses， 2017， 10（1）： 8.
[21]	XIAO Q Q， GUO D Y， CHEN S L. Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy［J］. Front Cell Infect Microbiol， 2019， 9： 69.
[22]	MEDIOUNI S， CHINTHALAPUDI K， EKKA M K， et al. Didehydro-cortistatin A inhibits HIV-1 by specifically binding to the unstructured basic region of tat［J］. mBio， 2019， 10（1）： e02662-18.
[23]	ZHOU C L， HUANG Y F， LI Y B， et al. A new small-molecule compound， Q308， silences latent HIV-1 provirus by suppressing tat- and FACT-mediated transcription［J］. Antimicrob Agents Chemother， 2021， 65（12）： e0047021.
[24]	CAFARO A， SCHIETROMA I， SERNICOLA L， et al. Role of HIV-1 tat protein interactions with host receptors in HIV infection and pathogenesis［J］. Int J Mol Sci， 2024， 25（3）： 1704.
[25]	AJASIN D， EUGENIN E A. HIV-1 tat： role in bystander toxicity［J］. Front Cell Infect Microbiol， 2020， 10： 61.
[26]	ASAMITSU K， FUJINAGA K， OKAMOTO T. HIV tat/P-TEFb interaction： a potential target for novel anti-HIV therapies［J］. Molecules， 2018， 23（4）： 933.
[27]	RAZOOKY B S， PAI A， AULL K， et al. A hardwired HIV latency program［J］. Cell， 2015， 160（5）： 990-1001.
[28]	DONAHUE D A， KUHL B D， SLOAN R D， et al. The viral protein Tat can inhibit the establishment of HIV-1 latency［J］. J Virol， 2012， 86（6）： 3253-3263.
[29]	DEMARCHI F， D’ADDA DI FAGAGNA F， FALASCHI A， et al. Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1［J］. J Virol， 1996， 70（7）： 4427-4437.
[30]	TA T M， MALIK S， ANDERSON E M， et al. Insights into persistent HIV-1 infection and functional cure： novel capabilities and strategies［J］. Front Microbiol， 2022， 13： 862270.
[31]	LIN X， IRWIN D， KANAZAWA S， et al. Transcriptional profiles of latent human immunodeficiency virus in infected individuals： effects of Tat on the host and reservoir［J］. J Virol， 2003， 77（15）： 8227-8236.
[32]	ALI A， MISHRA R， KAUR H， et al. HIV-1 Tat： an update on transcriptional and non-transcriptional functions［J］. Biochimie， 2021， 190： 24-35.
[33]	LIANG T Z， ZHANG Q， WU Z Y， et al. UHRF1 suppresses HIV-1 transcription and promotes HIV-1 latency by competing with p-TEFb for ubiquitination-proteasomal degradation of tat［J］. mBio， 2021， 12（4）： e0162521.
[34]	KONG W L， BISWAS A， ZHOU D W， et al. Nucleolar protein NOP2/NSUN1 suppresses HIV-1 transcription and promotes viral latency by competing with Tat for TAR binding and methylation［J］. PLoS Pathog， 2020， 16（3）： e1008430.
[35]	LU H S， LI Z C， XUE Y H， et al. Viral-host interactions that control HIV-1 transcriptional elongation［J］. Chem Rev， 2013， 113（11）： 8567-8582.
[36]	AOKI S， WATANABE Y， SANAGAWA M， et al. Cortistatins A， B， C， and D， anti-angiogenic steroidal alkaloids， from the marine sponge Corticium simplex［J］. J Am Chem Soc， 2006， 128（10）： 3148-3149.
[37]	RICE A P. Unexpected mutations in HIV-1 that confer resistance to the tat inhibitor didehydro-cortistatin A［J］. mBio， 2019， 10（4）： e01547-19.
[38]	KESSING C F， NIXON C C， LI C， et al. In vivo suppression of HIV rebound by didehydro-cortistatin A， a “block-and-lock” strategy for HIV-1 treatment［J］. Cell Rep， 2017， 21（3）： 600-611.
[39]	MOUSSEAU G， KESSING C F， FROMENTIN R， et al. The tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency［J］. mBio， 2015， 6（4）： e00465.
[40]	LI C， MORI L， VALENTE S T. The block-and-lock strategy for human immunodeficiency virus cure： lessons learned from didehydro-cortistatin A［J］. J Infect Dis， 2021， 223（12 ）： 46-53.
[41]	MEDIOUNI S， JABLONSKI J， PARIS J J， et al. Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice［J］. Curr HIV Res， 2015， 13（1）： 64-79.
[42]	MEREDITH L W， SIVAKUMARAN H， MAJOR L， et al. Potent inhibition of HIV-1 replication by a tat mutant［J］. PLoS One， 2009， 4（11）： e7769.
[43]	JIN H P， LI D S， SIVAKUMARAN H， et al. Shutdown of HIV-1 transcription in T cells by nullbasic， a mutant tat protein［J］. mBio， 2016， 7（4）： e00518-16.
[44]	RUSTANTI L， JIN H P， LOR M， et al. A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes［J］. Virol J， 2017， 14（1）： 52.
[45]	LIN M H， SIVAKUMARAN H， JONES A， et al. A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1［J］. Retrovirology， 2014， 11： 121.
[46]	FRALDI A， VARRONE F， NAPOLITANO G， et al. Inhibition of tat activity by the HEXIM1 protein［J］. Retrovirology， 2005， 2： 42.
[47]	LEOZ M， KUKANJA P， LUO Z P， et al. HEXIM1-Tat chimera inhibits HIV-1 replication［J］. PLoS Pathog， 2018， 14（11）： e1007402.
[48]	LUO H， VONG C T， CHEN H B， et al. Naturally occurring anti-cancer compounds： shining from Chinese herbal medicine［J］. Chin Med， 2019， 14： 48.
[49]	LIANG X， XIE R X， SU J F， et al. Inhibition of RNA polymerase Ⅲ transcription by Triptolide attenuates colorectal tumorigenesis［J］. J Exp Clin Cancer Res， 2019， 38（1）： 217.
[50]	WAN Z T， CHEN X L. Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein［J］. Retrovirology， 2014， 11： 88.
[51]	HERMAN A B， TSITSIPATIS D， GOROSPE M. Integrated lncRNA function upon genomic and epigenomic regulation［J］. Mol Cell， 2022， 82（12）： 2252-2266.
[52]	LI J， CHEN C C， MA X C， et al. Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation［J］. Nat Commun， 2016， 7： 11730.
[53]	JEONG E， MARTINA J A， CONTRERAS P S， et al. The FACT complex facilitates expression of lysosomal and antioxidant genes through binding to TFEB and TFE3［J］. Autophagy， 2022， 18（10）： 2333-2349.

Research progress in therapeutic strategy of human immunodeficiency virus type 1 latenty by targeting Tat

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 53

Related Articles 3

Metrics

Comments

Recommended 0

[1]	Guofeng HUANG,Congyi LI,Hong WANG,Wenyan ZHANG. Research progress in inhibitors of structural protein Gag-Pol of human immunodeficiency virus and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1156-1163.
[2]	GUO Wei,MENG Xiao-jun,QIU Bai-hong,MENG Xiang-dong,WANG Lu,QIN Qian-qian,DING Zh. Estimation and projection of HIV epidemic among high-risk population in Jilin province [J]. J4, 2011, 37(4): 754-758.
[3]	YANG Huai-ning,XU Hui,PU Yun,YU Xiang-hui,ZHANG Yu,ZHAO Da-li,SUN Zhi-wei. Expression and preliminary activity identification of several linked antigen epitopes of consensce genes of HIV [J]. J4, 2008, 34(2): 217-220.